Figure 1From: Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survivalHepatitis B virus (HBV) status and hepatitis outcome in 278 hepatitis B surface antigen (HBsAg)-negative patients with CD20+ diffuse large B-cell lymphoma (DLBCL). HBeAb, hepatitis B e antibody; HBsAb, hepatitis B surface antibody.Back to article page